Pipeline: External Programs

Allarity is actively engaged in external program collaborations to advance these promising clinical programs through development.


DeflexifolTM, an optimized all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5FU) and its biomodulator leucovorin (LV),  is being developed by FivepHusion including Allarity’s DRP® companion diagnostics in the clinical trial design.


LiPlaCis®, a target controlled liposome formulation of one of the world’s most widely used chemotherapeutic agents, cisplatin. The specific LiPlaCis formulation allows delivery of LiPlaCis directly to the tumor site where is it needed. Allarity completed the initial Phase 2, DRP-guided proof-of-concept trial in metastatic breast cancer that showed promising results. LiPlaCis had been out licensed to Chosa Oncology AB. Chosa will advance the development of LiPlaCis® in late stage metastatic breast cancer in an expanded phase 2 trial.


2X-111 (Glutathione-enhanced, PEGylated Liposomal Doxorubicin), a novel drug candidate that is designed for the liposomal delivery of the anti-cancer drug doxorubicin directly to a tumor, with a glutathione coating added to exploit active endogenous transporters, allowing the drug to cross the blood-brain barrier. 2X-111 has also previously demonstrated clinical activity against brain metastasis in breast cancer, which remains a second priority indication for this asset.  Allarity has out-licensed 2X-111 to Smerud Research International AS to progress late stage development in for the treatment of glioblastoma multiform (GBM) (primary brain cancer) and potentially brain metastases of breast cancer (mBC).